1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Hawthorn Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Hawthorn Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 26 pages

Hawthorn Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Hawthorn Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the Hawthorn Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Hawthorn Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Hawthorn Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Hawthorn Pharmaceuticals, Inc. - Brief Hawthorn Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Hawthorn Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Hawthorn Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Hawthorn Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Hawthorn Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Hawthorn Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Hawthorn Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Hawthorn Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Hawthorn Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

Hawthorn Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Hawthorn Pharmaceuticals, Inc. Snapshot 4
Hawthorn Pharmaceuticals, Inc. Overview 4
Key Information 4
Key Facts 4
Hawthorn Pharmaceuticals, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Hawthorn Pharmaceuticals, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Hawthorn Pharmaceuticals, Inc. - Pipeline Products Glance 9
Hawthorn Pharmaceuticals, Inc. Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Hawthorn Pharmaceuticals, Inc. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Hawthorn Pharmaceuticals, Inc. - Drug Profiles 11
CSPG4 Monoclonal Antibody 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Haw AD-14 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Haw mAb-11 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Haw mAb-12 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Haw Nuv-15 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Haw Nuv-16 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Haw S-13 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Hawthorn Pharmaceuticals, Inc. - Pipeline Analysis 18
Hawthorn Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 18
Hawthorn Pharmaceuticals, Inc. - Pipeline Products By Target 20
Hawthorn Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 21
Hawthorn Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action 22
Hawthorn Pharmaceuticals, Inc. - Recent Pipeline Updates 23
Hawthorn Pharmaceuticals, Inc. - Locations And Subsidiaries 24
Head Office 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 26
Disclaimer 26

List of Tables

Hawthorn Pharmaceuticals, Inc., Key Information 4
Hawthorn Pharmaceuticals, Inc., Key Facts 4
Hawthorn Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Hawthorn Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Hawthorn Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Hawthorn Pharmaceuticals, Inc. - Phase I, 2013 9
Hawthorn Pharmaceuticals, Inc. - Preclinical, 2013 10
Hawthorn Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 19
Hawthorn Pharmaceuticals, Inc. - Pipeline By Target, 2013 20
Hawthorn Pharmaceuticals, Inc. - Pipeline By Route of Administration, 2013 21
Hawthorn Pharmaceuticals, Inc. - Pipeline Products By Mechanism of Action, 2013 22
Hawthorn Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 23

List of Figures

Hawthorn Pharmaceuticals, Inc. - Pipeline by Indication, 2013 6
Hawthorn Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 7
Hawthorn Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 8
Hawthorn Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2013 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.